KARD

11.8305.51%
LA

Leslie A. Leinwand

Co-Founder

Dr. Leslie A. Leinwand, Ph.D., serves as Venture Partner at Catalio Capital Management, LP. She is a Co-Founder at Kardigan, Inc. She is Member of Scientific and Medical Advisory Board at Avery Therapeutics, Inc. She served as Member of Scientific Advisory Board at Edgewise Therapeutics, Inc. She serves as a Member of Scientific Advisory Board at Fulcrum Therapeutics, Inc. She is the chief scientific officer of the BioFrontiers Institute at the University of Colorado. She established and co-directs the University of Colorado’s Cardiovascular Research Institute (CU-CVI). Dr. Leinwand is a renowned muscle physiologist with broad expertise in the genetic underpinnings of heart and skeletal muscle defects. She serves at Board of Directors of Hiberna, Global Down Syndrome Foundation. She serves on Scientific Advisory Board of Bristol Myers Squibb, Edgewise Therapeutics, Fulcrum Therapeutics, Linda Crnic Institute for Down Syndrome, Contour Therapeutics, TARA Biosystems. She serves on External Advisory Board of University of Arizona Department of Physiology; Indiana University School of Medicine; Stanford Cardiovascular Institute. She is Distinguished Professor of Molecular, Cellular and Developmental Biology, University of Colorado at Boulder, Cardiology, Molecular Biology, Human Genetic Disease. She is a Howard Hughes Medical Institute Professor. She co-founded MyoKardia, Inc. in 2012, which was acquired by Bristol Myers Squibb. She is Co-Founder of Myogen, which was acquired by Gilead Pharmaceuticals and Hiberna. She has authored more than 350 scientific publications. Dr. Leinwand received her Bachelor of Science degree from Cornell University and her Doctor of Philosophy at Yale University and completed her postdoctoral training at Rockefeller University.

Positions